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Integration of liquid biopsy
and pharmacogenomics for precision therapy
of EGFR mutant and resistant lung cancers
Jill Kolesar1, Spencer Peh1, Levin Thomas2, Gayathri Baburaj2, Nayonika Mukherjee2, Raveena Kantamneni2,
Shirley Lewis3, Ananth Pai4, Karthik S. Udupa4, Naveena Kumar AN5, Vivek M. Rangnekar6 and Mahadev Rao2*

Abstract
The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating
the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effective treatment of
EGFR mutant and resistant lung cancer. This review appraises current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic (PGx) testing as precision therapy tools in the management of EGFR
mutant and resistant lung cancers. Liquid biopsy could play a potential role in selection of precise tyrosine kinase
inhibitor (TKI) therapies during different phases of lung cancer treatment. This selection will be based on the driver
EGFR mutational status, as well as monitoring the development of potential EGFR mutations arising during or after
TKIs treatment, since some of these new mutations may be druggable targets for alternative TKIs. Several studies have
identified the utility of liquid biopsy in the identification of EGFR driver and acquired resistance with good sensitivities
for various blood-based biomarkers. With a plethora of sequencing technologies and platforms available currently,
further evaluations using randomized controlled trials (RCTs) in multicentric, multiethnic and larger patient cohorts
could enable optimization of liquid-based assays for the detection of EGFR mutations, and support testing of CYP450
enzymes and drug transporter polymorphisms to guide precise dosing of EGFR TKIs.
Keywords: EGFR, Liquid biopsy, Lung cancer, Pharmacogenomics, Precision therapy, Tyrosine kinase inhibitors
Introduction
More than 19.3 million new cases of cancer were
reported worldwide in 2020. Globally, lung cancer is the
leading cancer that accounts for 11.4% of all cases and is
also the leading cause of cancer related deaths [1]. Over
the previous 20 years, a focus on genomics research has
led to the identification of genomic drivers of lung cancer. The first identified and most broadly studied is epidermal growth factor receptor (EGFR), a transmembrane
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receptor tyrosine kinase that is part of the ErbB family.
EGFR activating mutations act to amplify downstream
phosphorylation cascade signaling, resulting in increased
cell proliferation and survival. Activating EGFR mutations are the known drivers of lung cancer that accounts
for approximately 10 to 15% of non-small cell lung cancer
(NSCLC) diagnoses [2–5] and assessment of EGFR mutations is now routinely performed as standard of care.
Tissue biopsy is the gold standard for selecting targeted
therapies for NSCLC and current guidelines recommend
liquid biopsies to guide initial therapeutic decisions
in advanced NSCLC only if obtaining a tissue biopsy is
not feasible [6–8]. However, when compared to tissue
biopsies, liquid biopsies are less invasive, do not rely on
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obtaining a tissue biopsy, reduce procedural complications, and importantly can serve as a tool for monitoring EGFR treatment resistance and efficacy. Serial liquid
biopsy monitoring throughout a patient’s treatment can
allow researchers to identify and understand genomic
resistance mechanisms [9–13].
Many liquid biopsies in development are blood-based
but testing methods are highly variable. Metastases from
a primary tumor requires multiple biological processes
that include invasion into the vascular circulation, seeding in distant tissue, and forming a vascular network
necessary for cellular survival and proliferation [14].
Blood-based liquid biopsies exploit these tumor characteristics to detect cellular components or genomic contents released by cancer cells into the peripheral blood
[14, 15]. Next generation sequencing (NGS) technology has allowed improved detection of cell free DNA
(cfDNA) or circulating tumor DNA (ctDNA) and are the
only clinically validated methods as companion diagnostics for EGFR mutated NSCLC [16, 17]. Several other
blood-based liquid biopsies in development include circulating tumor cells (CTCs), microRNA (miRNA), long
non-coding RNA (lncRNA), exosomes, and tumor-educated platelets (TEPs) that have the potential for diagnostics, prognostics, and predicting treatment resistance in
EGFR mutated lung cancer [18–26]. Liquid biopsies of
pleural effusion fluid are another promising method that
is currently being investigated to potentially overcome
the limitations of peripheral blood liquid biopsies [27].
An often-overlooked aspect of precision therapy is
pharmacogenetic (PGx) variations in drug metabolism.
Approximately 80% of drugs available in the United
States are metabolized via the cytochrome 450 (CYP450)
pathway, including the majority of EGFR TKIs [28, 29].
CYP450 is a family of enzymes involved in oxidation
or conjugation of xenobiotics, rendering drugs more
hydrophilic and eventually allowing for renal excretion
[29, 30]. In addition, multi-drug resistant transporter
proteins (MDRPs) such as permeability glycoprotein
(P-gp) or breast cancer resistant protein (BCRP) influence xenobiotic transport [31]. P-gp and BCRP are ATPbinding cassette proteins and act as efflux transporters
of xenobiotics, including some EGFR inhibitors [32].
Single nucleotide polymorphisms (SNPs) in CYP450s
and MDRPs cause variations in pharmacokinetic (PK)
and pharmacodynamic (PD) properties of drugs across
disease states including cancer [29, 30]. Germline PGx
variations in CYP450s and MDRPs can impact the PK/
PD properties of EGFR TKIs and subsequently result in
increased toxicity or decreased efficacy in certain subsets of the patient population. Pre-emptive testing of germline PGx is not yet standard of care in oncology. With
the increasing use of liquid biopsies in clinical practice,
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there are opportunities to incorporate germline PGx testing given other incidental findings of germline mutations
in patients [33]. Such an integrated approach of liquid
biopsy and PGx testing could pave the way for precision therapy in lung cancer by tumor detection, dynamic
monitoring of EGFR mutations and acquired resistance,
as well as aid in the selection of precise drug therapy via
serial molecular profiling from blood as shown in Fig. 1.
The purpose of this review is to summarize current literature, opportunities, and challenges for liquid biopsy
and PGx testing as precision therapy tools in the management of EGFR mutated lung cancer.

EGFR TKIs therapy and resistance
The EGFR gene encodes a transmembrane protein having 1186 amino acids, with the extracellular region/
ectodomain accounting for 621 residues [34]. The EGFR
gene comprises 28 exons, with the exons 18-21 coding
for ATP-binding within the tyrosine kinase domain [35].
Human EGFR is a transmembrane glycoprotein with
a glycosylated extracellular domain that binds peptide
growth factor ligands, a single transmembrane region,
and a cytoplasmic domain with tyrosine kinase activity
that plays a key role in the regulation of cellular proliferation, differentiation, survival, and metastasis [36–39].
Actionable driver mutations detected in patients with
advanced NSCLC are sensitizing EGFR mutations, which
affect about 50% of Asians and 15% of Caucasians [40,
41]. Exon 19 deletions and exon 21 L858R point mutations are the most prevalent EGFR sensitizing mutations, accounting for approximately 90% of mutations
in NSCLC and leading to high sensitivity to TKIs [40,
42–46].
Traditionally, platinum-based chemotherapy was the
first-line therapy for advanced non-small cell lung cancer
(NSCLC). Regardless of clinical characteristics, guidelines recommend that all advanced lung adenocarcinoma
patients should be tested for EGFR mutations [47, 48].
Lung adenocarcinoma patients should be assessed for
oncogenic drivers and treated with targeted therapy [49]
if targetable mutations are present. EGFR TKIs are suggested as the primary therapy for EGFR-mutant patients
by the European Society for Medical Oncology (ESMO)
[47], American Society of Clinical Oncology (ASCO)
[50], and the National Comprehensive Cancer Network
(NCCN) [51]. In patients with an EGFR mutation, EGFR
TKIs considerably improved clinical outcomes, such as
progression-free survival (PFS) and overall response rate
(ORR). Patients with lung adenocarcinoma and EGFR
mutation have a response rate of up to 81.6% and a PFS
of approximately 9.7 to 13.3 months [43]. For metastatic
NSCLC patients with EGFR mutations, several phase
III clinical trials have found that first-generation and
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Fig. 1 Serial molecular profiling by liquid biopsy and pharmacogenomics across various phases of lung cancer such as screening, treatment
planning, monitoring of pharmacotherapy till remission free stage for precision therapy of EGFR mutant and resistant lung cancer. Created with
BioRender.com (Agreement number: FS237SI0R8). Abbreviations: EGFR: Epidermal growth factor receptor; TKIs: Tyrosine kinase inhibitors; PGx:
Pharmacogenomics; TDM: Therapeutic drug monitoring

second-generation TKIs are more efficacious than firstline platinum-based chemotherapy [52]. Although most
patients with an EGFR mutation are likely to benefit from
EGFR TKIs, many develop progressive disease within a
year of initiating therapy [53]. Furthermore, long-term
efficacy of EGFR TKIs is reduced by acquired resistance.
History of EGFR TKIs development

The first EGFR inhibitor, gefitinib, was initially approved
for the treatment of NSCLC regardless of mutation
status based on phase II data, which did not translate to improved outcomes in large phase III trials and
led to the withdrawal of gefitinib from the US market
unless patients were receiving the drug and benefiting
[54]. Around that time, reports emerged regarding the
importance of EGFR mutations in predicting response
to EGFR inhibitors [55–57]. Subsequent studies of the
first-generation EGFR TKIs enrolled patients based on
EGFR mutation status and compared outcomes to front
line chemotherapy. Gefitinib and erlotinib demonstrated
improved PFS in comparison to chemotherapy and were
approved as first-line therapy for individuals with EGFRmutated NSCLC. However, overall survival (OS) was
similar, suggesting development of resistance or high
rates of cross-over from the chemotherapy arms after
trial completion [44, 58–60].

After approvals in the front-line setting, subsequent
EGRF inhibitors were compared to gefitinib or erlotinib.
Afatinib is another first-generation EGFR TKI which
demonstrated a time to treatment failure of 13.7 versus
11.5 months when compared to gefitinib [61]. Osimertinib was assessed in trials that enrolled patients with
EGFR L858R (FLAURA), exon 19 deletion (FLAURA),
and T790M (AURA3). Osimertinib demonstrated significant OS benefits in the FLAURA trial [62] but not in
the AURA3 trial [63]. Despite overcoming EGFR T790M
mutation in NSCLC, patients will usually develop other
resistance mechanisms, resulting in loss of EGFR TKIs
efficacy. Therefore, there is a dire need to understand and
monitor treatment resistance mechanisms for further
therapy development. Aside from efficacy and resistance,
another pertinent aspect of precision oncology for EGFR
TKIs is the tolerability of toxicities in different patient
populations.
Mechanisms of acquired resistance to EGFR TKIs

Disease progression (based on WHO criteria or RECIST)
while on EGFR TKIs is often caused by EGFR resistance
to the treatment. It is a major hurdle to overcome in providing the most efficacious treatment to individuals with
EGFR-mutant NSCLC [64]. Usually, acquired resistance
to EGFR TKIs evolves after a median of 9.2–14.7 months
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[44, 45, 59, 65]. Target gene modification, alternative pathway activation, and histological or phenotypic
transformation are the three prevalent mechanisms of
acquired resistance to EGFR TKIs [66] (Fig. 2).
EGFR‑dependent mechanism: target gene modification

EGFR T790M mutation, which replaces methionine
with threonine at position 790 in exon 20 of EGFR, is
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a common mechanism of resistance to EGFR TKIs. It
accounts for 50–60% of the cases [67, 68]. T790M may
promote EGFR TKIs such as gefitinib, erlotinib, and
afatinib resistance by generating steric hindrance to
TKIs binding to the ATP-binding pocket, or by increasing EGFR’s ATP binding affinity. The T790M mutation
in EGFR may restore the mutant receptor’s affinity for
ATP, lowering the effectiveness of competitive inhibitors

Fig. 2 Schematic diagram explaining mechanisms of acquired resistance to EGFR TKIs. A. Mutant EGFR confers resistance to binding of TKIs to the
tyrosine kinase domain of EGFR. This activates downstream signaling pathways such as the PI3K-AKT pathway, JAK-STAT pathway, RAS pathway
and ERK-MAPK pathway. B. Overexpression of HGF causes TKI-resistance that activates downstream signaling of the PI3K-AKT pathway, JAK-STAT
pathway, RAS pathway and ERK-MAPK pathway. The above pathways result in cell proliferation, cell migration, invasion, and metastasis, that in
turn cause the release of CTCs, ctDNA, miRNA, lncRNA, exosomes and TEPs into the bloodstream. Liquid biopsy helps examine these biomarkers
and assess the type of mutation. Created with BioRender.com (Agreement number: XF237SHT72). Abbreviations: EGFR: Epidermal growth factor
receptor; TK: Tyrosine kinase; CTCs: Circulating tumor cells; ctDNA: Circulating tumor DNA; miRNA: Micro RNA; lncRNA: Long non-coding RNA; TEPs:
Tumor educated platelets; mTOR: Mammalian target of rapamycin; AKT: V-akt murine thymoma viral oncogene homolog; PI3K: Phosphoinositide
3-kinase; STAT3: Signal transducer and activator of transcription 3; JAK: Janus Activated Kinase; ERK: Extracellular-signal-regulated kinase; MAPK:
Mitogen-activated protein kinase; MEK: Mitogen-activated protein kinase kinase; RAF: Rapidly Accelerated Fibrosarcoma; RAS: Rat sarcoma virus;
HGF: Hepatocyte growth factor; TKIs: Tyrosine kinase inhibitors; MET: Mesenchymal epithelial transition factor
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[67, 69]. Detection of EGFR T790M status is important
since it affects treatment choice indicating the use of the
third-generation EGFR TKI, osimertinib as a second-line
therapy [70].
EGFR‑independent mechanism: alternative pathway
activation

The activation of alternative or bypass pathways can also
produce acquired resistance. The most prevalent bypass
mechanism is MET amplification, accounting for 5–10%
of patients with resistance to TKIs [66, 71, 72]. The MET
gene encodes the receptor tyrosine kinase c-MET, and
binding of MET to its ligand, hepatocyte growth factor
(HGF), causes tyrosine phosphorylation of the receptor
and initiation of downstream signaling pathways, such
as phosphoinositide 3-kinase (PI3K) and V-akt murine
thymoma viral oncogene homolog (AKT), signal transducer and activator of transcription 3 (STAT3), rat sarcoma virus (RAS), and mitogen-activated protein kinase
(MAPK). Combination trials of MET directed therapies
and T790M targeting inhibitors are important because
MET amplification and T790M mutation are not mutually exclusive [73]. MET gene amplification can initiate
PI3K-AKT pathway independently of EGFR by ERBB3
dimerization and signaling [72]. However, the MET
amplification threshold that confers acquired resistance to TKI-therapy is yet to be determined. EGFR TKIs
resistance is also promoted by overexpression of HGF,
the ligand of MET oncoprotein [74]. Other alternative
mechanisms that have been reported to cause resistance to TKIs, including KRAS mutation, BRAF mutation
[75, 76], HER2 amplification [77], phosphatidylinositol
4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) mutation [78], and enhanced expression
of the receptor tyrosine kinase AXL [79].
Histological and phenotypic transformation

During or after treatment with EGFR TKIs, a subset of
individuals (i.e., 5–10%) with NSCLC and EGFR mutations develops histologic transformation of adenocarcinoma into small-cell lung cancer (SCLC) [78, 80–82].
Prolonged EGFR inhibition in NSCLC can result in the
appearance of SCLC-like histologic, genetic, and pharmacological sensitivity profiles. The epithelial-to-mesenchymal transition (EMT) program has also been linked
to SCLC transformation, as demonstrated by decreased
expression of E-cadherin and enhanced expression of
vimentin [78]. EMT was reported as a mechanism of
resistance to TKIs, with EMT identified in 2 of 37 (i.e.,
5%) patients in tumor specimens obtained after EGFR
treatment and SCLC transformation [78]. Slug, ZEB1,
Snail, and AXL are examples of EMT transcription
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factors that undergo alterations due to acquired resistance to TKIs [83, 84].
Liquid biopsy in EGFR mutant NSCLC detection
Comparative superiority over tissue biopsy‑studies
with results in EGFR mutant/resistant lung cancer

Liquid biopsy efficiently analyzes CTCs, ctDNA, miRNA,
lncRNA, exosomes, and TEPs [23, 25, 26, 85]. Table 1
summarizes the characteristics of the biomarkers with
their corresponding isolation techniques, clinical applications, and limitations. ctDNAs formed by the DNA fragments are released into the bloodstream by cell death,
especially via necrosis [103, 104]. ctDNA can be extracted
from a variety of bodily fluids, including saliva, sputum,
CSF, urine, and pleural secretions, in addition to plasma
[105, 106]. Despite its moderate sensitivity, urine ctDNA
is a viable alternative for detecting EGFR mutations
[107]. With a concordance of 84.62% among all patients,
[108] tissue biopsy and liquid biopsy using ctDNA can
have distinct effects on the prognosis and treatment
strategies of EGFR mutant non-small cell lung adenocarcinoma. Although ctDNA is approved for the detection
of EGFR mutant in NSCLC patients, [109] adenocarcinomas are more likely to be detected by the established
miRNA markers over squamous cell carcinoma [110]. A
retrospective study of 308 lung cancer patients who had
re-biopsy and 118 patients who had liquid biopsy, found
that 134 patients (43.5%) in the re-biopsy group and 49
patients (41.5%) in the liquid biopsy group tested positive
for EGFR T790M. The liquid biopsy’s specificity and sensitivity for detecting T790M was 84.4 and 34%, respectively. The study showed that 75.0% of the patients in the
liquid biopsy group and 52.3% of the patients in the rebiopsy group, who tested positive for T790M mutation
were likely to get treated by a third-generation TKI [10].
Sacher et al. prospectively assessed 180 patients to determine the correlation between tissue re-biopsy and liquid
biopsy. The sensitivity, specificity, and positive predictive value of ctDNA based T790M detection using digital
droplet polymerase chain reaction (ddPCR) was reported
to be 77.1, 63.2, and 79%, respectively [111].
In liquid biopsy, the plasma samples are predominantly analyzed using quantitative polymerase chain
reaction (qPCR), digital PCR (dPCR) or ddPCR, and
NGS [112]. Feng Li et al. compared the concordance
of electric field-induced release and measurement
(EFIRM)-based liquid biopsy with ddPCR to establish
the superiority of the former. The study concluded a
100% sensitivity for EFIRM as opposed to 84.6% sensitivity in the detection of EGFR mutation in plasma samples. This is because of the limitation of PCR to amplify
short DNA fragments (shorter than 70 bps) [113].
The largest prospective, multicenter trial on cfDNA
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Table 1 The characteristics of the biomarkers with their corresponding isolation techniques, clinical applications and limitations
Biomarkers

Isolation technique

Circulating tumor cells (CTCs)

Immunomagnetic enrichment

▪ Prognosis
▪ Treatment

Immunomagnetic isolation

▪ Diagnosis
▪ Prognosis

Magnetic beads

▪ Prognosis
▪ Treatment

Microfluidic positive immunocapture
(CTC-chip)
Size based separation
(filter-based isolation)
Density gradient separation

Inertial focusing

Single cell sequencing

Circulating tumor DNA (ctDNA)

Clinical application

▪ Prognosis
▪ Diagnosis

▪ Prognosis
▪ Treatment

▪ Prognosis
▪ Treatment

▪ Prognosis
▪ Diagnosis
▪ Treatment

▪ Prognosis
▪ Treatment

▪ Detection
Automated (ccfDNA purification) ▪ Prognosis
▪ Treatment initiation and
monitoring

Manual (DNA purification)

Limitations

▪ Reproducibility
▪ Sensitivity
▪ CTC without epithelial marker
could not be detected
▪ Difficult to use with whole
blood
▪ Low purity of detected CTC
▪ Cannot process whole blood
▪ High detection cost
▪ Reliance on EpCAM and CK
▪ Variation of expression of
EpCAM and CK across cancers
▪ Lack of selectivity
▪ High detection cost

▪ Increased contamination with
WBC
▪ Requires more blood
▪ Shear force might affect cell
viability and attachment
▪ Slow rate processing
▪ Limited volume

References
[86]

[87]

[88]

[89]

▪ Prone to clogging
[90]
▪ Requires high volume of blood
▪ Sample may be adulterated
▪ Loss of large CTC and cell
aggregates
▪ Low purity

▪ Morphological deformation of
the captured cell
▪ Poor reproducibility
▪ False positives and false negatives
▪ Allele deletion
▪ Sequencing errors
▪ Low accuracy and precision

▪ Requires adequate control for
downstream application
▪ Only for use with plasma prepared from human whole blood
samples collected in EDTA tube
▪ Not for use in diagnostic
procedures

[91]

[92]

[93]

[94]
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Table 1 (continued)
Biomarkers

Isolation technique

ctRNA (miRNA, lncRNA)

Northern blot analysis

▪ Diagnosis

Microarray

▪ Diagnosis
▪ Therapeutic response prediction

RT-qPCR

▪ Diagnosis
▪ Treatment initiation and
monitoring

Liquid chip technology

Exosomes

Clinical application

Ultracentrifugation-based

▪ Diagnosis
▪ Prognosis
▪ Treatment
▪ Resistance monitoring
▪ Early diagnosis
▪ Prognosis

Size-based

▪ Diagnosis

Immunoaffinity capture-based

▪ Diagnosis

Microfluidics based

▪ Diagnosis

Tumor-educated platelets (TEPs) Spliced TEP mRNA

▪ Diagnosis
▪ Treatment monitoring

Limitations

▪ mRNA degradation during
electrophoresis
▪ Low sensitivity
▪ Detection with multiple
probes is difficult

▪ Standardization and optimization
▪ Low specificity
▪ Low reproducibility
▪ High cost of a single experiment
▪ Unsuitable for clinical experiences
▪ Amplification bias
▪ No template controls
▪ Cannot perform multiple
detection
▪ In vivo validation
▪ Difficult to scale up

▪ Contamination and exosome
loss
▪ Low recovery
▪ Laborious
▪ Deformation of EVs
▪ High risk of chip clogging
▪ Long run time

▪ Antibody cross reactivity
▪ Possible detection of non-EV
particles
▪ Only exosomes with targeted
proteins can be separated
▪ Low yield
▪ Tumor heterogeneity hinders
immune recognition
▪ Time consuming
▪ Expensive
▪ Lack of standardization and
method validation
▪ Moderate to low sample
capacity

▪ Complex isolation technique
▪ Fragility of TEPs

References
[95]

[96]

[97]

[88]

[98]

[99]

[98]

[100]

[101, 102]

Abbreviations: CTCs Circulating Tumor Cells, EpCAM Epithelial cell adhesion molecule, CK Cytokeratin, WBC White blood cell, ctDNA Circulating tumor DNA, ccfDNA
Circulating cell free DNA, EDTA Ethylenediamine tetraacetic acid, ctRNA Circulating tumor RNA, miRNA MicroRNA, lncRNA Long non-coding RNA, mRNA Messenger
RNA, RT-qPCR Quantitative real-time polymerase chain reaction, EVs Extracellular vesicles, TEPs Tumor-educated platelets

conducted by Leighl et al. concluded that cfDNA testing could identify the biomarkers with a sensitivity
and specificity, comparable to tissue genotyping [114].
Use of cfDNA yielded faster results and increased the
biomarker discovery rate, although the median turnaround time (TAT) recorded in this study for the first
10 patients was 14 days (range, 11-30 days) and 7 days
(range, 5-9 days) for the last 10 patients [114]. Often
false negative results are obtained due to varied tumor

localization and volume, irregular cfDNA shedding
with tumor evolution [115] or patients receiving treatment [116]. A diagnostic tool comprising of a panel
of miR-21, miR-126, miR-210, miR-486-5p detected
NSCLC with a sensitivity and specificity of 86.2 and
96.5% respectively [110]. The SensiScreen® EGFR Liquid kit that was commercially launched recently detects
EGFR mutations (T790M, L858R, exon 19 deletions) at
a higher sensitivity and specificity, which outperforms
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the established assay platforms with a robust ability to
detect single copy mutations [117].
LncRNAs could serve as potential predictive and
prognosis markers for EGFR resistant and mutant lung
cancers as, they have been implicated in the regulation
of chemosensitivity, radiosensitivity, and sensitivity of
EGFR targeted therapies in lung cancers through diverse
mechanisms [25]. LncRNA LINC00460 overexpression in
EGFR-mutant lung adenocarcinoma was reported to be
associated with poorer response to EGFR TKI therapies.
Drug molecules that could target knockdown or knockout of LINC00460 may represent potential therapeutic
strategy for overcoming EGFR TKIs resistance and consequently improve the prognosis of EGFR mutant lung
cancer patients [118]. LncRNA bladder cancer associated transcript 1 (BLACAT1) knockdown was reported
to reverse afatinib resistance in NSCLC through modulation of STAT3 signalling [119]. Several other lnRNAs
such as BC087858, metastasis associated lung adenocarcinoma transcript 1 (MALAT-1) have been implicated in
the promotion of EGFR TKIs resistance in lung cancer
via regulation of EMT process [120]. T790M mutation
detection by simultaneously capturing and interrogating
exosomal RNA/DNA and cfDNA (exoNA) had 92% sensitivity and 89% specificity using results of tumor biopsy
as gold standard [26]. Another qPCR- based test that
assessed mutations within EGFR using exoNA of NSCLC
patients reported an overall sensitivity of 90% for L858R,
83% for T790M and 73% for exon 19 indels with specificities of 100, 100, and 96% respectively [121]. Combined
approach of using exosomal RNA and ctDNA among
EGFR mutant NSCLC patients improved sensitivity of
EGFR mutation detection [122]. Using short length exosomal DNA and RNA (exoTNA) of 200 bp length could
potentially serve to be a sensitive biomarker for detection
of EGFR mutants in NSCLC patients having low copy
numbers of target mutation [123]. Several TEP biomarkers that could potentially be utilized for early screening of NSCLC have been reported [23]. Early stage and
late-stage NSCLC were detected with an accuracy of 81
and 88% respectively from TEP RNA biomarker panel
[124]. EGFR mutation detection in NSCLC patients was
observed with 87% accuracy using the TEP-derived RNA
analysis [125].
Utility in detecting acquired resistance to EGFR TKIs

EGFR T790M mutation was reported to be the primary acquired resistance to TKI therapy, followed by
MET amplification, HER2 amplification and epithelial
to mesenchymal transition [126, 127]. The AURA2 trial
investigated the efficacy of osimeritinib, an irreversible tyrosine kinase inhibitor, in treating patients with
advanced NSCLC and either EGFR-TKI sensitizing
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or EGFR T790M mutations. The trial demonstrated a
median PFS of 9.9 months and osimertinib was well tolerated among the treated patients [128]. Consistently, the
AURA Phase II extension study demonstrated a median
PFS of 12.3 months with a tolerable safety profile [129].
Based on these findings, osimeritinib is now regarded in
the first line of treatment in patients with EGFR T790M
mutant NSCLC. Over the course of treatment with first
or second-generation TKIs, patients usually acquire
several mutations, including EGFR, BRAFV600E, and
ERBB2 mutations; ALK, ROS1, NTRK, and RET fusion;
MET amplification and MET exon 14 skipping variants
that can be assessed to identify patients for subsequent
targeted therapy [114].
Until recently, the only way to identify T790M status
was by re-biopsy of tumor tissue. However, liquid biopsy
genotyping has recently become a more appealing option
to tissue re-biopsy, particularly for detecting the growing
number of resistance mutations that may develop during therapy [71, 78]. Several studies have addressed the
usefulness of liquid biopsy in detecting molecular alterations that cause resistance mechanisms [130, 131]. The
first report of ctDNA study with T790M in plasma was
published in 2009 [132]. The identification of T790M by
whole-exome sequencing of ctDNA using longitudinal
blood-based EGFR testing was initially reported in 2013
[133]. Utilizing both ctDNA and CTCs, many studies
have demonstrated the value of using liquid biopsies to
detect EGFR resistance mutations [134–141]. Based on
this finding, the NCCN and the ESMO guidelines both
suggest plasma genotyping as an alternative to tissuebased testing, although secondary re-biopsy is recommended to confirm a negative plasma evaluation of
T790M [6, 142]. Resistance of T790M mutants to EGFR
TKIs was studied by analyzing ctDNA using CAPP-Seq
in patients treated with rociletinib [141]. Chabon et al.
identified a shorter PFS accompanied with novel resistance mechanism (activating KRAS, EGFR L798I) upon
treatment with a third-generation TKI [141]. A study
conducted by Rachiglio et al. investigated the role of
concomitant driver mutations (MET, ERBB2, NRAS,
BRAF, KRAS, PIK3CA) on the outcome of 133 NSCLC
patients who received TKIs. Patients with concomitant
driver mutations had a significantly lower PFS than
those with only an EGFR mutation (7 vs. 11.3 months;
p = 0.04) implying that a subset of EGFR mutant tumors
have concomitant driver mutations, that could affect the
efficacy of first-generation EGFR TKIs [143]. Another
cfDNA analysis reported that after progression on EGFR
TKIs, 48.5% of plasma samples were positive for KRAS
mutation, with 39.4% of those having a KRAS and EGFR
co-mutation [144]. Though SCLC transformation is difficult to detect with liquid biopsy, a recent study showed
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that ctDNA can be examined in terms of changes in
global copy number to track its dynamics in patients
with SCLC transformation [145]. The mechanism of
SCLC transformation is still largely undefined. However,
it is possible that deletion of the retinoblastoma gene
(RB) plays a role [146]. Completed and ongoing trials on
liquid biopsy for the detection of EGFR mutant NSCLC
are tabulated in the Supplementary Table 1 [147].
Utility in detecting prognosis

Tumor mutational burden (TMB), a surrogate for overall
neo-antigen load [148] can be analyzed using tissue and
blood-based assays. The CheckMate-026 trial reported
an association between high tissue TMB (tTMB) and the
clinical efficacy of nivolumab in NSCLC. An independent
association between blood TMB (bTMB) and PFS prediction in patients receiving atezolizumab monotherapy was
reported in NSCLC patients. The study also exemplified
a high concordance between bTMB and tTMB when run
on the same ctDNA sample [149]. A liquid biopsy with
NGS can help detect tumor progression and accompanying multiple genetic alterations [150]. The trial, Tracking
Non–small-Cell Lung Cancer Evolution Through Therapy (TRACERx) by Hanjani et al. analyzed chromosomal
instability and genome doubling prospectively by whole
exome sequencing (WES) to assess the driver events in
NSCLC to predict a poor prognosis. Altered genomic
co-occurrence with tumor progression was inferred to
influence the patient’s response to TKIs [151]. A group
of advanced EGFR mutant patients were assessed for
multiple co-occurring genetic alterations. cfDNA was
used to identify the co-occurrence of the genetic alterations within the WNT/CTNNB1, BRAF, MET, PIK3CA,
MYC, and the cell cycle pathways (CDKN2A loss and
CDK6 CNG). Analysis of longitudinal tumor biopsy

based whole exome sequencing and cfDNA was consistent with the genomic alterations [152]. Genomic profiling of ctDNA samples can identify therapeutic targets
by locating driver and resistance mutations Analysis of
the ctDNA of 8388 advanced lung adenocarcinoma and
NSCLC patients by 70 gene NGS panel (Guardant360
assay) identified oncogene driver mutations in 48.8% of
the samples, the most frequent mutations being EGFR
followed by KRAS. The study subsequently recorded a
65% increase in biomarker detection over tissue, where
one half of the patients received targeted therapy [153].
Oxnard et al. proposed plasma genotyping of cfDNA as
a screening method for T790M preceding EGFR resistance biopsy. However, with a 30% false negative rate of
plasma genotyping, tissue genotyping is still required for
some patients. Therefore, the concomitant use of tissue
and plasma genotyping is the new paradigm in determining T790M resistance management [154].

Pharmacogenomics of TKIs and implications
pertaining to PK/PD responses
Metabolism of EGFR TKIs

EGFR TKIs are small molecules that are highly protein
bound and metabolized via the CYP450 system. The
majority are also substrates of P-gp and BCRP [155]. P-gp
and BCRP are a family of ATP-binding cassette (ABC)
transporters and are encoded by the genes ABCB1 and
ABCG2, respectively [156, 157]. A summary of EGFR
TKI metabolism is listed in Table 2. Gefitinib is a firstgeneration EGFR TKI primarily metabolized by CYP3A4,
CYP2D6, and to a minor extent, CYP3A5 [158–163].
CYP1A1 may be involved in gefitinib metabolism but PK
implications have yet to be characterized since CYP1A1
is typically expressed in extrahepatic locations such as
the lungs [164]. Gefitinib is also known substrate of P-gp

Table 2 A summary of metabolism of EGFR TKIs drugs
EGFR TKIs

Generation Metabolism

Gefitinib

First

CYP3A4, CYP2D6,
CYP3A5 (minor)

Erlotinib

First

CYP1A2, CYP3A4

Afatinib

First

None

Dacomitinib

Second

CYP2D6

Osimertinib

Third

CYP3A4

Mobocertinib Third?

CYP3A4, CYP3A5

Drug-drug interactions

▪ CYP3A4, CYP2D6 inhibitors may increase serum concentration
▪ CYP3A4, CYP2D6 inducers may decrease serum concentration

▪ CYP3A4, CYP2A1 inhibitors may increase serum concentration
▪ CYP3A4, CYP2A1 inducers may decrease serum concentration
▪ Erlotinib reduce serum concentrations of other CYP3A4 substrates
▪ P-gp inhibitors may increase serum concentration
▪ P-gp inducers may decrease serum concentration

▪ CYP2D6 inhibitors may increase serum concentration

MDRP substrates
P-gp and BCRP
P-gp and BCRP

P-gp and BCRP

▪ CYP3A4 inhibitors may increase serum concentration
P-gp and BCRP
▪ CYP3A4 inducers may decrease serum concentration
▪ Osimertinib may increase serum concentrations of other P-gp/BCRP substrates
▪ CYP3A4/5 inhibitors may increase serum concentration
▪ CYP3A4/5 inducers may decrease serum concentration

None

Unknown

Abbreviations: TKIs Tyrosine kinase inhibitors, MDRP Multi-drug resistant transporter protein, P-gp Permeability glycoprotein, BCRP Breast cancer resistant protein
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and BCRP [165–167]. Erlotinib is primarily metabolized
by CYP1A2 and 3A4 but also induces 3A4 expression to
a minor extent [163, 168]. P-gp and BCRP may also contribute to erlotitnib clearance [169]. Afatinib is the only
EGFR TKI that is not metabolized via the CYP450 system due to its strong covalent binding to plasma proteins
and is primarily excreted through the feces [170, 171].
Afatinib is both a substrate and inhibitor of P-gp and
BCRP [170, 172, 173]. Dacomitinib is extensively metabolized by CYP2D6 into its active metabolite, contributing to the long half-life of the drug [174]. Dacomitinib’s
clearance is neither known to be impacted by P-gp nor
by BCRP [175]. Osimertinib is primarily metabolized by
CYP3A4, and is minimally cleared by P-gp and BCRP
[176, 177]. Mobocertinib is the newest oral EGFR TKI
that received accelerated approval in September 2021 by
the FDA for EGFR exon 20 deletion NSCLC. Mobocertinib is metabolized by CYP3A4 and 3A5 to form two
active metabolites [178]. It is unknown if mobocertinib is
a P-gp or BCRP substrate at this point.
Single nucleotide polymorphisms, allele frequencies
and phenotypes

Single nucleotide polymorphisms (SNPs) occur when a
single DNA base differs between individuals and varies
across race and ethnic groups [179]. SNPs are functionally categorized by phenotypic impact. In general, normal
metabolizers (NM) are present in majority of the population and have wild type functional enzyme activity. Ultrarapid metabolizers (UM) have increased enzyme activity
compared to normal metabolizers. Poor-metabolizers
(PM) have limited to no enzyme activity. Intermediate
metabolizers (IM) have enzyme activities between PM
and NMs [180]. The phenotypic impact of SNPs in drug
metabolizing enzymes can vary, ranging from benign to
a significant loss or gain of enzyme activity and phenotype reporting based on ethnicity, clinical guidelines, and
laboratories was inconsistent in previously published literature [181].
CYP2D6 accounts for 25% of all drug metabolism and
has the most polymorphic variability in the CYP450 family [182]. In 2019, consensus guidelines recommended
standardization of CYP2D6 phenotype definitions based
on an activity score [183, 184]. Notably, inconsistencies
in phenotype assignments may occur due to changes to
phenotype definition as more evidence become available
[182, 185]. Although CYP3A4 is the major metabolizer
of drugs and its polymorphic variability has been extensively studied, there is little evidence supporting a role for
CYP3A4 polymorphisms in changing the metabolism of
substrates. One possible explanation could be the structural similarities between subfamilies, leading to erroneous identification of CYP3A4 [186, 187]. The CYP1A2
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-163C > A SNP polymorphism (haplotype CYP1A2*1F)
has increased enzyme activity for substrates such as caffeine and is the most well characterized CYP1A2 polymorphism [188]. However, at present, there is a lack of
evidence for assigning CYP1A2 phenotypes due to relative infancy CYP1A2 polymorphism research. Similarly,
SNP polymorphisms of ABCB1 and ABCG2 have been
reported, however but currently, standardized definitions
for phenotypes are lacking.
Smoking, CYP1A2, polymorphisms and erlotinib

Cigarette smoke produces polycyclic aromatic hydrocarbons (PAH), a class of compounds known to induce the
expression of CYP1A2 [189, 190]. Several hypotheses
point towards a transcriptional mechanism for CYP1A2
induction by PAH. PAH may act as a ligand for arylhydrocarbon receptor, which is an intracellular receptor
involved in downstream signaling of CYP1A2 transcription [191, 192]. Another explanation may be epigenetic
changes via chromatin remodeling and reduced expression of histone deacetylase 2 resulting in increased transcription of CYP1A2 [193, 194]. Induction of CYP1A2
expression increases clearance of erlotinib leading to
reduced plasma exposure and subsequently lowering efficacy [195]. Even though EGFR mutations occur
more frequently in non-smokers with lung cancer, managing smokers and former smokers on erlotinib treatment remains challenging clinically. Smokers and former
smokers had a 3.9% response rate compared to 24.7% in
a selected subset of population on erlotinib [196]. The
higher number of former and current smokers may also
have contributed to minimal OS benefit in the overall
population. Later erlotinib trials that enrolled patients
based on EGFR mutation status demonstrated significantly improved efficacy of erlotinib. However, smokers
or former smokers still made up approximately 30% of
the study population [58, 126, 197] that may likely reflect
the proportion of smokers or former smokers with EGFR
mutated lung cancer in the real world. A pharmacokinetic model demonstrated a decrease in erlotinib exposure by more than 20% in patients exposed to cigarette
smoking [198]. Another study has also showed that doubling erlotinib dose from 150 mg to 300 mg in current
smokers resulted in similar plasma concentrations of
erlotinib compared to non-smokers on 150 mg dose, suggesting a potential need for higher doses of erlotinib to
achieve adequate efficacy [199]. Based on the study by
Hughes et al. up to 300 mg once daily of erlotinib is recommended for current smokers.
Despite studies suggesting the detrimental impact of
smoking on erlotinib exposure and efficacy, there are still
varying extents of CYP1A2 induction by cigarette smoking that could be due to other epigenetic factors affecting
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CYP1A2 expression [200–203]. Polymorphisms in the
NR1I3 gene which codes for the constitutive androstane
receptor is known to upregulate the transcription of
CYP1A2 [200, 204]. Constitutive androstane receptor is
also known to interact with the PAH pathway of CYP1A2
induction. Another epigenetic factor may be due to
the influence of methylation on CYP1A2 expression in
hepatocytes [205]. Previous literature also suggests that
certain CYP1A2 polymorphisms such as CYP1A2*1F
may be induced to a larger extent in smokers [202, 203].
Contributions to erlotinib metabolism by CYP3A4, P-gp,
and BCRP, may also explain the variation in CYP1A2
induction by cigarette smoke. Therefore, there is currently limited recommendation for phenotype definition
and lack of guidelines for CYP1A2 based PGx testing
with erlotinib use.
Polymorphisms in CYP3A4

Phenotyping studies assessing the effect of CYP3A4
variants on erlotinib metabolism were inconclusive and
pre-emptive testing is not currently recommended. A
PK study in a Korean population showed no difference
in AUC exposure and C
 max of erlotinib in patients with
CYP3A4 polymorphisms [206]. In a similar study, a polymorphism in CYP1A2*1 M resulted in a higher Cmax. One
explanation for the lack of evidence for supporting PGx
guided dosing for erlotinib may be due to multiple metabolic pathways involved in erlotinib clearance. Another
contributing factor could be auto-induction of CYP3A4
by erlotinib. CYP450 induction often occurs on a transcriptional level and takes up to 2 weeks for increased
expression, which may be missed in studies that do not
assess steady state erlotinib levels [206, 207]. There are
limited studies evaluating the impact of CYP3A4 SNPs
and gefitinib, osimertinib, and mobocertinib metabolism. Furthermore, there is a lack of evidence suggesting
that CYP3A4 polymorphisms alter PK/PD parameters of
EGFR TKIs. Similar to CYP1A2, phenotypes for CYP3A4
are yet to be defined and there is lack of guidance supporting testing for CYP3A4 polymorphisms to guide dosing of EGFR TKIs.
Polymorphisms in CYP2D6

Numerous studies have evaluated associations of gefitinib adverse effects, such as rash and hepatotoxicity, in
patients who have reduced CYP2D6 metabolizing phenotypes. A study enrolled Japanese patients who developed transaminitis after starting gefitinib, but did not
find significant differences in CYP2D6 polymorphisms
[208, 209]. Similarly, another study assessing Japanese
patients who were extensive metabolizers (EM) and IMs
of CYP2D6 found higher active metabolite concentrations, but higher concentrations were not associated
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with increased adverse effects [209]. In a third study in
Japanese patients, Suzumura et al. reported patients with
CYP2D6 *10/*10 polymorphism, defined as a reduced
activity phenotype, had an increased risk of rash with
gefitinib compared to patients on erlotinib [210]. The
conflicting evidence supporting a relationship between
increased gefitinib adverse effects and CYP2D6 polymorphisms are multifactorial. This may partly be explained
by the fact that previous studies utilized the EM or rapid
metabolizer phenotype of CYP2D6, which has been
removed and re-classified under NM [183]. The lack of
standardized CYP2D6 definitions that may also have contributed to differences in testing and selection of alleles of
interest remains a challenge today [211]. A recent study
of dacomitinib in Chinese patients with IM and EM
CYP2D6 polymorphisms found insignificant changes to
exposure of primary metabolite of dacomitinib between
the two groups [212]. However, it was noted by the
authors that CYP2D6 EM in the Chinese population had
a 53.5% metabolite to parent exposure ratio compared to
25.4% in a Western CYP2D6 EM population, suggesting
that polymorphism and PGx testing may be impacted by
ethnicity.
Polymorphisms in ABCB1 and ABCG2

P-gp and BCRP are primarily expressed along the luminal intestinal wall and blood brain barrier and prevent
diffusion of xenobiotics across membranes into the
blood circulation and central nervous system, respectively [31]. Polymorphisms in ABCB1 and ABCG2, have
been shown to correlate with expression of P-gp and
BCRP, respectively. ABCB1 and ABCG2 polymorphisms
resulting in increased expression of P-gp and BCRP may
reduce bioavailability of a substrates like gefitinib, erlotinib, afatinib and osimertinib resulting in lower systemic
exposure [213, 214]. On the other hand, reduced expression of P-gp and BCRP has been purported to increase
bioavailability resulting in increased toxicities [167, 215].
Endo-Tsukude et al. reported marginal increase in rash
among Japanese patients harboring ABCB1 1236C > T
genotypes, however the differences were not significant
[216]. A study led by Fukudo and colleagues found that
Japanese patients harbouring ABCG2 421C > A SNP polymorphism had increased plasma exposure of erlotinib
which is associated with increased diarrhea [217]. However, another study in Japanese patients by Akasaka et al.
did not find an increased risk of diarrhea in patients with
ABCG2 421C > A polymorphism [218].
An increase in P-gp and BCRP activity or expression
along the luminal membrane of the blood brain barrier
may decrease central nervous system (CNS) penetration
of EGFR TKIs. In vitro and preclinical models of gefitinib,
[165, 166] erlotinib, [219–221] and osimertinib [177]
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have suggested that less CNS penetration was achieved
in patients with increased expression of P-gp and BCRP.
A decrease in CNS penetration can have detrimental
impacts on patients with CNS metastases, which confers
poorer prognosis. Alternatively, a decreased expression
of P-gp and BCRP may theoretically increase CNS toxicity although there is no evidence published yet.
In addition to germline PGx differences in P-gp and
BCRP, cancer cells have been shown to upregulate
expression of these transporters and prevent chemotherapy from reaching their intracellular target tissue.
Increased P-gp and BCRP contributes to chemoresistance and subsequent treatment failure.
Current evidence does not support a role for pharmacogenetic dose adjustment of EGFR TKIs. Available studies are usually small, with variable methodologies and
conflicting results. Larger studies that comprehensively
evaluate the impact of polymorphisms on drug exposure
and outcome are needed to optimize precision dosing as
shown in Fig. 3.
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Alternative strategies and future directions

It is generally accepted that plasma concentrations are
associated with drug effects, both efficacy and toxicity.
While SNPs contribute to drug plasma concentrations,
a variety of other factors, including drug-drug interactions, food effects, and body size are other contributing
factors. By directly measuring drug concentrations, and
adjusting dose based on concentration, therapeutic dose
monitoring (TDM) can potentially overcome factors that
limit the utility of PGx testing. Many analytical methods
are reported for erlotinib, [222–225] gefitinib [225–229]
and osimertinib [230, 231]. Despite the abundance of
methods for detecting EGFR TKI plasma concentrations,
TDM of EGFR TKIs are not yet clinically validated or
implemented routinely in practice. Identification of a target concentration associated with activity, as well as clinical trials demonstrating that TDM outperforms routine
clinical care is required prior to clinical implementation.
Cancer cells are known to develop chemoresistance
through upregulation of ABCB1 and ABCG2 expression,

Fig. 3 Pharmacogenomic screening of CYP450 enzymes and drug transporters for TKIs could help in stratifying the population into various
categories of drug responders. Created with BioRender.com (Agreement number: II237SHPD4). Abbreviations: PGx: Pharmacogenomics; TKI:
Tyrosine kinase inhibitors; BCRP: Breast cancer resistant protein; P-gp: Permeability glycoprotein; IM: Intermediate metabolizers; PM: Poor
metabolizers; EM: Extensive metabolizers; UM: Ultra rapid metabolizers; DDI: Drug-drug interaction
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preventing chemotherapy from reaching the target tissue. Gefitinib, erlotinib, afatinib, and osimertinib, are
substrates of P-gp and BCRP, and a potential strategy is
to combine these agents with P-gp inhibitors, thereby resensitizing tumors to chemotherapy. Ongoing studies are
required to develop these potentially effective combinations. Liquid biopsies can complement such synergistic
strategies in clinical practice by testing for upregulation
in P-gp and BCRP expression throughout a patient’s
treatment.
Traditionally, early phase dose finding clinical trials rely
upon a “3 + 3” maximum tolerated dose design. The paradigm shift toward targeted therapy has called for different
approaches for optimizing targeted therapy dosing [232].
Preclinical models of targeted therapies utilize receptor saturation or inhibition of phosphorylation activities
during the drug development process. It has been shown
that EGFR saturation in preclinical models corresponds
to anti-tumor efficacy [233]. A small number of studies,
including gefitinib, have utilized EGFR receptor saturation as part of an endpoint in phase 1 studies [234–236].
However, it is unclear if adequate EGFR receptor saturation is correlated to efficacy and toxicity and receptor
turnover as a result of EGFR TKIs binding, as there is a
potential limitation in measuring receptor saturation due
to the short half-life of about 12 h [237, 238].
Immunotherapy has been explored as an alternative
or complementary therapeutic strategy among lung cancer patients, particularly in those with TKIs resistance
and/or in advanced stages of EGFR mutant lung cancers and are unaffected by the genetic polymorphisms
of drug metabolizing enzymes and/or transporters [239,
240]. EGFR-directed monoclonal antibodies such as
cetuximab, necitumumab, panitumumab, matuzumab
and nimotuzumab can bind on to EGFR present on the
surface of tumor cells and prevent the binding of the
ligand epidermal growth factor (EGF) in the extracellular
domain, resulting in inhibition of EGFR signalling. These
monoclonal antibodies could also inhibit EGFR signaling by other mechanisms including antibody dependent
cellular toxicity (ADCC) [241]. However, lack of significant clinical benefits with the combination therapy
of EGFR-directed monoclonal antibodies with TKIs in
EGFR mutant lung cancer patients warrants the need for
further evidence [242]. Immune check point inhibitors
(ICIs), comprising of monoclonal antibodies against programmed cell death protein-1 (PD-1) such as nivolumab,
pembrolizumab and programmed death-ligand1 (PDL1) such as atezolimumab and durvalumab, have been
reported to improve the clinical response in few subsets
of lung cancer patients. However, majority of the available reports suggest that EGFR-mutant lung cancer
patients have shown poorer response to ICIs treatment

Page 13 of 22

[243–246]. Several factors such as lower PD-L1 expression and tumor mutational burden, increased risk of
pulmonary toxicity in patients on prior or concurrent
osimertinib therapy, limited efficacy with ICIs monotherapy and risk of developing hyper-progressive disease
(HPD), warrant caution for their use in EGFR mutant
lung cancer patients [246, 247].

Challenges of liquid biopsy‑based detection
and PGx of EGFR mutation and resistant lung
cancer
EGFR T790M mutation accounts for only about half
of the resistance mechanisms in NSCLC patients who
developed acquired resistance to first or second-generation TKIs. Liquid biopsy may not be able to detect
other resistance mechanisms, such as small cell cancer transformation [80]. Several rare EGFR mutations
are known to cause conformational alterations in the
EGFR drug binding region. However, their influence
on TKIs responses is still debated and require further
clinical validation [248, 249]. Some liquid biopsy assays
have been reported to have a lower sensitivity for EGFR
mutations compared to tissue biopsy that may be attributed to sampling from different tumor cell populations
as well as differing sequencing technologies [137, 250].
An increased frequency of EGFR T790M detection correlated with tumor progression/ metastasis by liquid
biopsy and is explained by low copy number in peripheral blood in early stage, that may pose problems for
early screening of lung cancer by liquid biopsy [138,
251]. Further, the TMB in EGFR-mutated tumors was
shown to be significantly lower than in EGFR wild-type
tumors [252]. Robust implementation of liquid biopsy as
a clinical tool in the management of EGFR resistant lung
cancer warrants further harmonization of the diverse
ctDNA analysis technologies and different platforms,
and requires multicentric randomized controlled trials
with larger cohorts of patients and controls [253]. Harmonization of PGx guidelines among different consortia
and agencies and lack of compliance among physicians
for PGx label-based testing and prescribing present key
challenges in the implementation of pharmacogenomicsbased therapy management in clinics [254]. PGx does not
offer information on the post-translational modifications
of encoded proteins, therefore the importance of this
element in cancer therapy requires additional investigations [255]. Implications of other interacting factors on
genetic polymorphisms of CYP450 enzymes and drug
transporters such as various patient specific factors, ethnicity, epigenomics, lifestyle, drug-drug and drug-dietary
interactions could pose challenges in deriving appropriate genotyping-based dosage implementation at an
individual level in clinics [255–257]. Most importantly,
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Fig. 4 Challenges faced by liquid biopsy and PGx for their implementation in clinical practice for EGFR resistant and mutant lung cancer
patients. Abbreviations: PGx: Pharmacogenomics; EGFR: Epidermal growth factor receptor; TKIs: Tyrosine kinase inhibitors; PTM: Post translational
modifications; DDI: Drug-drug interaction; MRD: Minimal residual disease; TMB: Tumor mutational burden

currently there is a lack of guidelines supporting testing
of CYP450 and drug transporter polymorphisms to guide
dosing of EGFR TKIs. A summary of these limitations is
represented in Fig. 4.

Conclusion
While tissue remains the most accepted material for
molecular profiling of solid tumors such as lung cancers,
it is limited by the dynamic and heterogenous nature of
cancer resulting in spontaneous occurrence of clonal
evolution and drug resistance. Liquid biopsy has emerged
as an imperative alternative and/or complementary tool
to tissue biopsy for molecular profiling in lung cancer
due to its relative advantages such as being minimally
invasive, reduced procedural complications, as well as
its utility for longitudinal monitoring of patients for
monitoring acquired resistance to TKIs. An integrated
approach of employing liquid biopsy and PGx for serial
molecular profiling of EGFR mutant and resistant lung
cancer patients at an individual level as well as at population subsets could represent a potential precise screening
and monitoring tool in this era of precision oncology by
identifying precise doses of TKIs against targetable EGFR
mutations. Though significant progress has been made
in these fields, several aspects related to their successful
implementation in practice, such as framing of robust

guidelines, harmonization of sequencing technologies
and platforms, multicentric validation in larger patient
cohorts, and identification of various interacting factors
needs to be addressed before clinical adoption at a global
scale.
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